Detection of TERC amplification in cervical epithelial cells for the diagnosis of high-grade cervical lesions and invasive cancer: A multicenter study in China

Journal of Molecular Diagnostics

Volumn 12, Issue 6, 2010, Pages 808-817

  Jiang, Jing ^a   Wei, Li Hui ^a   Li, Ya Li ^b   Wu, Rui Fang ^c   Xie, Xing ^d   Feng, You Ji ^e   Zhang, Guo ^a   Zhao, Chao ^a   Zhao, Yun ^a   Chen, Zhong ^f  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PEKING UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; VIRUS DNA;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CYTOLOGY; DISEASE COURSE; EPITHELIUM CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; RECEIVER OPERATING CHARACTERISTIC; RNA GENE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM; WART VIRUS; YOUDEN INDEX;

HUMAN PAPILLOMAVIRUS;

EID: 78049407607     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2010.100021     Document Type: Article

References (34)

1. World Health Organization Reproductive Health and Research, Chronic Diseases and Health Promotion. Comprehensive cervical cancer control: a guide to essential practice. Geneva: World Health Organization 2006, 3-4
2. Wei LH: Excessiveness and insufficiency in the diagnosis and treatment of cervical lesions. Chin J Clin Obstet Gynecol 2009, 10:83-84
3. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N: Forum Group Members; Bethesda 2001 Workshop: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119
4. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 ASCCP-Sponsored Consensus Conference: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007, 11:201-222
5. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T: Overview of the European and North American studies on HPV testingin primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101
6. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J: Human papillomavirus and papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597
7. Qiao YL, Sellors JW, Eder PS, Bao Y, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT: A new HPV-DNA test for cervical-cancer screening in developing regions: a crosssectional study of clinical accuracy in rural China. Lancet Oncol 2008, 9:929-936
8. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M: A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002, 94:1406-1414
9. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K: Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004, 78:11451-11460
10. Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Philip J, Lundsteen C: Comparative genomic hybridization reveals non-random chromosomal aberrations in early preinvasive cervical lesions. Cancer Genet Cytogenet 2001, 129:47-51
11. Hopman AH, Theelen W, Hommelberg PP, Kamps MAF, Herrington CS, Morrison LE, Speel EJ, Smedts F, Ramaekers FC: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 2006, 210:412-419
12. Zheng PS, Iwasaka T, Zhang ZM, Pater A, Sugimori H: Telomerase activity in Papanicolaou smear-negative exfoliated cervical cells and its association with lesions and oncogenic human papillomaviruses. Gynecol Oncol 2000, 77:394-398
13. Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T: Genomic amplification of the human telomerase gene (TERC) in Pap smears predicts the development of cervical cancer. Am J Pathol 2005, 166:1229-1238
14. Caraway NP, Khanna A, Dawlett M, Guo M, Guo N, Lin E, Katz RL: Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecol Oncol 2008, 110:37-42
15. Ramsaroop R, Oei P, Ng D, Kumar N, Cotter PD: Cervical intraepithelial neoplasia and aneusomy of TERC: assessment of liquid-based cytological preparations. Diagn Cytopathol 2009, 37:411-415
16. Tu Z, Zhang A, Wu R, Jiang J, Li Y, Wulan N, Li J, Zhang Y, Li Y, Chen Z, Wei L: Genomic amplification of the human telomerase RNA gene for differential diagnosis of cervical disorders. Cancer Genet Cytogenet 2009, 191:10-16
17. Jiang J, Tu Z, Zhang G, Li JR, Zhao LJ, Zhao C, Cui SH, Li XP, Chen Z, Wei LH: Evaluation of genomic amplification of the human telomerase RNA component gene in the screening of cervical lesions. Chin J Obstet Gynecol 2008, 43:849-853
18. Buckley CH, Butler EB, Fox H: Cervical intraepithelial neoplasia. J Clin Pathol 1982, 35:1-13
19. Youden WJ: Index for rating diagnostic tests. Cancer 1950, 3:32-35
20. Ferreccio C, Bratti MC, Sherman ME, Herrero R, Wacholder S, Hildesheim A, Burk RD, Hutchinson M, Alfaro M, Greenberg MD, Morales J, Rodriguez AC, Schussler J, Eklund C, Marshall G, Schiffman M: A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:815-823
21. Heselmeyer-Haddad K, Janz V, Castle PE, Chaudhri N, White N, Wilber K, Morrison LE, Auer G, Burroughs FH, Sherman ME, Ried T: Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol 2003, 163:1405-1416
22. zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009, 384:260-265
23. Malpica A, Matisic JP, Niekirk DV, Crum CP, Staerkel GA, Yamal JM, Guillaud MH, Cox DD, Atkinson EN, Adler-Storthz K, Poulin NM, Macaulay CA, Follen M: Kappa statistics to measure interrater and intrarater agreement for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis and methodologic issues. Gynecol Oncol 2005, 99:S38-52
24. Andersson S, Sowjanya P, Wangsa D, Hjerpe A, Johansson B, Auer G, Gravitt PE, Larsson C, Wallin KL, Ried T: and others. Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. Am J Pathol 2009, 175:1831-1847
25. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL: Canadian Cervical Cancer Screening Trial Study Group: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357:1579-1588
26. Alameda F, Espinet B, Corzo C, Munoz R, Bellosillo B, Lloveras B, Pijuan L, Gimeno J, Salido M, Solé F, Carreras R, Serrano S: 3q26 (hTERC) gain studied by fluorescence in situ hybridization as a persistence-progression indicator in low-grade squamous intraepithelial lesion cases. Hum Pathol 2009, 40:1474-1478
27. Jalali GR, Herzog TJ, Dziura B, Walat R, Kilpatrick MW: Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. Am J Obstet Gynecol 2010, 202:581.e1-e5
28. Solomon D, Schiffman M, Tarone R: ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001, 93:293-299 (Pubitemid 32219816)
29. Sherman ME, Schiffman M, Cox JT: Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002, 94:102-107
30. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 American Society for Colposcopy and Cervical Pathology- sponsored Consensus Conference: 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007, 197:340-345
31. Cox JT, Schiffman M, Solomon D: ASCUS-LSIL Triage Study (ALTS) Group: Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003, 188:1406-1412
32. Shlay JC, Dunn T, Byers T, Barón AE, Douglas JM Jr: Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears. Obstet Gynecol 2000, 96:410-416
33. Wu S, Meng L, Wang S, Ma D: A comparison of four screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005, 91:189-193
34. Bhatla N, Dar L, Patro AR, Kumar P, Kriplani A, Gulati A, Iyer VK, Mathur SR, Sreenivas V, Shah KV, Gravitt PE: Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol 2009, 33:446-450